← Back to Search

BPA Tool for Stroke Prevention in Atrial Fibrillation (SUPPORT-AF IV Trial)

N/A
Waitlist Available
Led By Alok Kapoor, MD
Research Sponsored by University of Massachusetts, Worcester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Patients under the age of 18
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test how well a shared clinical decision support tool can help 6 million Americans with atrial fibrillation get the right treatment to reduce their risk of stroke.

Who is the study for?
This trial is for adults with atrial fibrillation or flutter who've seen a primary care provider or heart specialist in the past year and have this condition noted in their health records. It's not for those under 18, pregnant women, prisoners, patients without an AF diagnosis, those with left atrial appendage closure, or hospice patients.
What is being tested?
The study tests if a decision support tool within electronic health records can increase prescription of oral anticoagulants (AC) to prevent strokes in AF patients. Providers are split into two groups: one uses the tool (intervention group), while the other doesn't (control group).
What are the potential side effects?
Since this trial involves using a decision support tool rather than medication, there are no direct side effects from interventions like drugs. However, increased AC use may lead to typical AC-related risks such as bleeding.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am younger than 18 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Initiation of Oral Anticoagulation (AC) Use
Length of Duration for Oral Anticoagulation (AC) Use
Secondary study objectives
Hospitalization for new Stroke, Transient Ischemic Attack, or Systemic Embolism Ischemic Attack /Systemic Embolism.
Incidence of Major Hemorrhage and Clinically Relevant non-major Bleeding

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Receive best practice advisory (BPA)
Group II: ControlActive Control1 Intervention
Does not receive best practice advisory (BPA)

Find a Location

Who is running the clinical trial?

University of Massachusetts, WorcesterLead Sponsor
362 Previous Clinical Trials
987,956 Total Patients Enrolled
7 Trials studying Atrial Fibrillation
36,309 Patients Enrolled for Atrial Fibrillation
University of FloridaOTHER
1,397 Previous Clinical Trials
761,933 Total Patients Enrolled
5 Trials studying Atrial Fibrillation
221 Patients Enrolled for Atrial Fibrillation
Alok Kapoor, MDPrincipal InvestigatorUMass Chan Medical School
4 Previous Clinical Trials
853 Total Patients Enrolled
3 Trials studying Atrial Fibrillation
691 Patients Enrolled for Atrial Fibrillation

Media Library

Atrial Fibrillation Research Study Groups: Intervention, Control
Atrial Fibrillation Clinical Trial 2023: Intervention Highlights & Side Effects. Trial Name: NCT05236556 — N/A
~408 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top